QR kód

A Review of Trastuzumab Biosimilars in Early Breast Cancer and Real World Outcomes of Neoadjuvant MYL-1401O versus Reference Trastuzumab

The reduced cost of trastuzumab biosimilars has led to increased adoption for HER2-positive breast cancer. This review of trastuzumab biosimilars encompasses this development and real world clinical data in early breast cancer. In addition, we present a retrospective study evaluating the total patho...

Celý popis

Uloženo v:
Hlavní autoři: Charlie Yang, Raida Khwaja, Patricia Tang, Nancy Nixon, Karen King, Sasha Lupichuk
Médium: Artigo
Jazyk:Inglês
Vydáno: MDPI AG 2022-06-01
Edice:Current Oncology
Témata:
trastuzumab
biosimilar
MYL-1401O
HER2+
breast cancer
early stage
On-line přístup:https://www.mdpi.com/1718-7729/29/6/337
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Podobné jednotky